INCYNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31
INCYTE CORP
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026
$113.25+0.18 (+0.16%)
Close on Oct 19, 2026
- Market cap
- $23.58B
- P/E (TTM)
- 14.4
- Dividend yield
- –
INCYTE CORP revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales | $4.97B | $4.54B | $4.35B | $4.15B | $3.96B | $3.81B | $3.62B | $3.46B | $3.28B | $3.20B | $3.17B | $3.07B | 85.3% | +25.3% |
| JAKAFI | $3.19B | $3.14B | $3.09B | $3.04B | $2.99B | $2.93B | $2.79B | $2.71B | $2.61B | $2.59B | $2.59B | $2.55B | 54.9% | +6.9% |
| OPZELURA | $988.00M | $702.77M | $678.46M | $632.77M | $584.08M | $541.27M | $508.29M | – | – | – | – | – | 17.0% | +69.2% |
| Product royalty revenues | $681.05M | $657.48M | $636.91M | $612.15M | $597.91M | $583.99M | $579.33M | $569.65M | $543.60M | $534.01M | $523.48M | $506.35M | 11.7% | +13.9% |
| JAKAVI | $485.62M | $471.14M | $457.73M | $441.69M | $431.79M | $421.39M | $418.84M | – | – | – | – | – | 8.3% | +12.5% |
| NIKTIMVO | $217.27M | $193.11M | $151.64M | $95.60M | $49.77M | $13.61M | $0 | – | – | – | – | – | 3.7% | +336.6% |
| MINJUVI/MONJUVI | $186.81M | $164.25M | $144.58M | $135.48M | $124.93M | $124.91M | $119.24M | $95.42M | $72.33M | $54.38M | $37.06M | – | 3.2% | +49.5% |
| Milestone and contract revenues | $173.20M | $167.00M | $150.00M | $50.00M | $23.00M | $18.00M | $43.00M | $45.00M | $32.00M | $32.00M | $7.00M | – | 3.0% | +653.0% |
| ZYNYZ | $145.76M | $104.74M | $66.35M | $35.98M | $14.00M | $5.73M | $3.19M | $2.39M | $1.80M | $1.72M | $1.25M | $668.00K | 2.5% | +941.4% |
| ICLUSIG | $141.66M | $139.99M | $134.07M | $127.22M | $119.39M | $113.52M | $114.32M | $114.08M | $112.06M | $114.28M | $111.62M | $112.11M | 2.4% | +18.7% |
| TABRECTA | $26.33M | $26.27M | $26.70M | $25.84M | $25.26M | $23.93M | $22.75M | – | – | – | – | – | 0.5% | +4.2% |
| Other | $13.90M | $9.86M | $7.88M | $4.74M | $3.30M | $2.89M | $2.17M | – | – | – | – | – | 0.2% | +321.3% |
| OLUMIANT Royalty Revenues | – | – | – | – | – | – | $135.57M | $137.45M | $132.27M | $132.57M | $136.14M | $131.64M | – | – |
| Milestone and contract revenues | – | – | – | – | – | – | – | – | – | – | – | $35.00M | – | – |
| PEMAZYRE | – | – | – | – | – | – | $81.75M | $79.26M | $77.54M | $78.84M | $83.64M | $86.01M | – | – |
| MINJUVI | – | – | – | – | – | – | – | – | – | – | $37.06M | $32.87M | – | – |
| PEMAZYRE Royalty Revenues | – | – | – | – | – | – | $2.17M | $2.52M | $2.63M | $2.10M | $1.97M | $2.49M | – | – |
By region
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $5.42B | $4.99B | $4.80B | $4.46B | $4.27B | $4.13B | $3.97B | – | – | – | – | – | 93.1% | +26.8% |
| Europe | $373.86M | $347.55M | $323.73M | $336.60M | $302.76M | $277.52M | $260.44M | – | – | – | – | – | 6.4% | +23.5% |
| Other countries | $28.07M | $23.62M | $17.57M | $14.00M | $10.95M | $7.75M | $6.21M | – | – | – | – | – | 0.5% | +156.2% |
From the segment and revenue-disaggregation notes of Incyte's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.